Table of Content
1. Report Prologue

2. Market Introduction

2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

3. Research Methodology

3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Chronic Kidney Disease Market, by Diagnosis

6.1 Introduction
6.2 Blood Test
6.2.1 Market Estimates & Forecast, 2020–2027
6.3 Urine Test
6.3.1 Market Estimates & Forecast, 2020–2027
6.4 Imaging Test
6.4.1 Market Estimates & Forecast, 2020–2027
6.5 Kidney Biopsy
6.5.1 Market Estimates & Forecast, 2020–2027

7. Global Chronic Kidney Disease Market, by Treatment

7.1 Introduction
7.2 Drugs
7.2.1 Market Estimates & Forecast, 2020–2027
7.3 Dialysis
7.3.1 Market Estimates & Forecast, 2020–2027
7.4 Kidney Transplant
7.4.1 Market Estimates & Forecast, 2020–2027

8. Global Chronic Kidney Disease Market, by Indication

8.1 Introduction
8.2 Type 1 or Type 2 Diabetes
8.2.1 Market Estimates & Forecast, 2020–2027
8.3 High Blood Pressure
8.3.1 Market Estimates & Forecast, 2020–2027
8.4 Polycystic Kidney Disease
8.4.1 Market Estimates & Forecast, 2020–2027

9. Global Chronic Kidney Disease Market, by End-User

9.1 Introduction

9.2 Hospital & Clinics
9.2.1 Market Estimates & Forecast, 2020–2027
9.3 Diagnostic Centers
9.3.1 Market Estimates & Forecast, 2020–2027

10. Global Chronic Kidney Disease Market, by Region

10.1 Introduction

10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K.
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies

12 Company Profiles

12.1 Abbott
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Siemens
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Beckman Coulter
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 F. Hoffmann-La Roche Ltd 
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 ACON Laboratories, Inc.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Nova Biomedical
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 ARKRAY
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis

12.8 AstraZeneca

12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis

12.9 GlaxoSmithKline Plc

12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis

12.10 Bayer AG

12.10.1 Overview
12.10.2 Product Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Others

13 Conclusion

13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of the Industry

14 Appendix